Clinical Scorecard: Integrating Prostate Health Index with Multiparametric MRI for Diagnosing Clinically Significant Prostate Cancer in Asian Populations

At a Glance

Key Highlights

• PHI outperforms total and free PSA in detecting clinically significant prostate cancer and reduces unnecessary biopsies.
• mpMRI with PI-RADS v2 scoring shows high sensitivity (0.89) and specificity (0.73) for csPC detection and can avoid unnecessary biopsies in ~27% of patients.
• Combining PHI and mpMRI may enhance diagnostic accuracy for csPC in Asian populations, though PHI availability and mpMRI insurance coverage remain limited.

Guideline-Based Recommendations

Diagnosis

• Use PHI (calculated as (p2PSA/free PSA) × √PSA) as a biomarker to improve specificity over PSA alone.
• Perform mpMRI using standardized PI-RADS v2 protocol to identify suspicious lesions prior to biopsy.
• Define clinically significant prostate cancer as grade group ≥2 (Gleason score ≥3+4).

Management

• Conduct cognitive registration targeted biopsy (TB) of mpMRI-identified lesions (PI-RADS ≥3) followed by systematic biopsy (SB).
• Consider PHI threshold ≥30 for diagnostic decision-making in Asian populations.

Monitoring & Follow-up

• Record and analyze biopsy results prospectively following START guidelines for MRI-targeted biopsy studies.
• Monitor biopsy tumor burden in relation to PHI levels.

Risks

• Unnecessary prostate biopsies may lead to complications such as bleeding, pain, and sepsis.
• Limited availability of PHI testing and lack of insurance coverage for mpMRI may restrict access.

Patient & Prescribing Data

Asian men with suspicion of prostate cancer due to elevated PSA or abnormal DRE

Integration of PHI and mpMRI prior to biopsy can improve detection of clinically significant prostate cancer and reduce unnecessary biopsies, optimizing patient selection for invasive procedures.

Clinical Best Practices

• Collect serum samples for PSA parameters prior to biopsy and process promptly (centrifuge within 3 hours, freeze at -20 to -80°C).
• Use a 3-Tesla MRI scanner with T2WI, DWI, and DCE sequences for mpMRI acquisition.
• Interpret mpMRI by experienced uroradiologists using PI-RADS v2 scoring system.
• Perform at least 2 biopsy cores per target lesion and a minimum of 12 systematic cores.
• Blinding clinicians to PHI results during biopsy decision-making to avoid bias.

References

• Global prostate cancer statistics and PSA screening
• PHI biomarker development and validation
• PI-RADS v2 guidelines and diagnostic performance
• START guidelines for MRI-targeted biopsy studies
• Meta-analysis of PHI in Asian populations